HLB’s Lirafugratinib Advances to European Review After U.S. Approval
Following its U.S. approval, HLB’s cholangiocarcinoma drug lirafugratinib has entered formal regulatory review for European market entry. About two weeks after receiving approval from the U.S. Food and Drug Administration (FDA), the drug has moved into the formal marketing authorization review proce
We haven't written up this one. BusinessKorea has the full story — the link below goes straight to it.